Articles from Casma Therapeutics

Casma Therapeutics, Inc., a biotechnology company engaging the autophagy and lysosomal systems to develop innovative new medicines, today announced that it has been awarded approximately $7.6 million in funding across two competitive grant programs from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). The non-dilutive funding supports a fully integrated preclinical development strategy for Casma’s lead program, CSM-101, enabling the company to generate new TRPML1 biomarker and IND-enabling data required to advance into first-in-human clinical studies.

Casma Therapeutics, a biotechnology company engaging the autophagy system to provide innovative new medicines, today announced that Keith Dionne, Ph.D., has stepped down as Chief Executive Officer, effective January 13, 2023. Dr. Dionne will continue to serve on the Board of Directors. Frank Gentile, Ph.D., formerly Chief Operating Officer of Casma, has been appointed as the new Chief Executive Officer and will also serve on the Board of Directors.